1. Sung, H. et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA. Cancer J. Clin. ahead of print (2021) doi:10.3322/caac.21660.
2. Loktionov, A. et al. Biomarker measurement in non-invasively sampled colorectal mucus as a novel approach to colorectal cancer detection: screening and triage implications. Br. J. Cancer123, 252–260 (2020).
3. Ogunwobi, O. O., Mahmood, F. & Akingboye, A. Biomarkers in colorectal cancer: Current research and future prospects. Int. J. Mol. Sci.21, 1–20 (2020).
4. Mármol, I., Sánchez-de-Diego, C., Dieste, A. P., Cerrada, E. & Yoldi, M. J. R. Colorectal carcinoma: A general overview and future perspectives in colorectal cancer. Int. J. Mol. Sci.18, (2017).
5. Toma, S. C., Ungureanu, B. S., Patrascu, S., Surlin, V. & Georgescu, I. Colorectal Cancer Biomarkers - A New Trend in Early Diagnosis. Curr. Heal. Sci. J.44, 140–146 (2018).
6. Yau, T. O., Tang, C. M., Harriss, E. K., Dickins, B. & Polytarchou, C. Faecal microRNAs as a non-invasive tool in the diagnosis of colonic adenomas and colorectal cancer: A meta-analysis. Sci. Rep.9, 1–13 (2019).
7. Turvill, J. et al. Diagnostic accuracy of one or two faecal haemoglobin and calprotectin measurements in patients with suspected colorectal cancer. Scand. J. Gastroenterol.53, 1526–1534 (2018).
8. Högberg, C., Karling, P., Rutegård, J. & Lilja, M. Diagnosing colorectal cancer and inflammatory bowel disease in primary care: The usefulness of tests for faecal haemoglobin, faecal calprotectin, anaemia and iron deficiency. A prospective study. Scand. J. Gastroenterol.52, 69–75 (2017).
9. Karl, J. et al. Improved Diagnosis of Colorectal Cancer Using a Combination of Fecal Occult Blood and Novel Fecal Protein Markers. Clin. Gastroenterol. Hepatol.6, 1122–1128 (2008).
10. Kim, Y. C. et al. The usefulness of a novel screening kit for colorectal cancer using the immunochromatographic fecal tumor M2 pyruvate kinase test. Gut Liver9, 641–648 (2015).
11. Guan‑Fu, W. J., Yi‑Hua, L. P. & Xin‑Min, S. Evaluation of fecal tumor m2 pyruvate kinase combined with fecal occult blood test as a detecting tool for colorectal cancer. J Sun Yat Sen Univ (Med Sci)27, 350‑353 (2006).
12. Shastri, Y. M. et al. Comparison of an established simple office-based immunological FOBT with fecal tumor pyruvate kinase type M2 (M2-PK) for colorectal cancer screening: Prospective multicenter study. Am. J. Gastroenterol.103, 1496–1504 (2008).
13. Mulder, S. A. et al. Tumor pyruvate kinase isoenzyme type M2 and immunochemical fecal occult blood test: Performance in screening for colorectal cancer. Eur. J. Gastroenterol. Hepatol.19, 878–882 (2007).
14. Vogel, T. et al. Vergleich verschiedener stuhltests zur detektion von neoplasien des kolon. Dtsch. Medizinische Wochenschrift130, 872–877 (2005).
15. Zaccaro, C. et al. Power of screening tests for colorectal cancer enhanced by high levels of M2-PK in addition to FOBT. Intern. Emerg. Med.12, 333–339 (2017).
16. Rutka, M. et al. Diagnostic accuracy of five different fecal markers for the detection of precancerous and cancerous lesions of the colorectum. Mediators Inflamm.2016, 2492081 (2016).
17. Parente, F. et al. A combination of faecal tests for the detection of colon cancer: A new strategy for an appropriate selection of referrals to colonoscopy? A prospective multicentre Italian study. Eur. J. Gastroenterol. Hepatol.24, 1145–1152 (2012).
18. Caviglia, G. P., Cabianca, L., Fagoonee, S. & Gili, F. M. Colorectal cancer detection in an asymptomatic population: Fecal immunochemical test for hemoglobin vs. Fecal M2-type pyruvate kinase. Biochem. Medica26, 114–120 (2016).
19. Cho Chi Hyun et al. Evaluation of the Performance of a Fecal Tumor M2-PK Rapid Kit Using Stool Specimens for Detection of Colorectal Tumors. Ann. Clin. Lab. Sci. 154–160 (2016).
20. Widlak, M. M. et al. Diagnostic accuracy of faecal biomarkers in detecting colorectal cancer and adenoma in symptomatic patients. Aliment. Pharmacol. Ther.45, 354–363 (2017).
21. Mowat, C. et al. Faecal haemoglobin and faecal calprotectin as indicators of bowel disease in patients presenting to primary care with bowel symptoms. Gut65, 1463–1469 (2016).
22. Kok, L. et al. Diagnostic accuracy of point-of-care fecal calprotectin and immunochemical occult blood tests for diagnosis of organic bowel disease in primary care: The cost-effectiveness of a decision rule for abdominal complaints in primary care (CEDAR) study. Clin. Chem.58, 989–998 (2012).
23. Alhadi, S. C. et al. The use of M2-pyruvate kinase as a stool biomarker for detection of colorectal cancer in tertiary teaching hospital: A comparative study. Ann. Coloproctol.36, 409–414 (2021).
24. Rigi, F. et al. Expression of tumor pyruvate kinase M2 isoform in plasma and stool of patients with colorectal cancer or adenomatous polyps. BMC Gastroenterol.20, (2020).
25. Dabbous, H. K. et al. Evaluation of Fecal M2PK as a Diagnostic Marker in Colorectal Cancer. J. Gastrointest. Cancer50, 442–450 (2019).
26. Sithambaram, S., Hilmi, I. & Goh, K. L. The diagnostic accuracy of the M2 pyruvate kinase Quick stool test-A rapid office based assay test for the detection of colorectal cancer. PLoS One10, (2015).
27. Wang, H. P., Wang, Y. Y., Pan, J., Cen, R. & Cai, Y. K. Evaluation of specific fecal protein biochips for the diagnosis of colorectal cancer. World J. Gastroenterol.20, 1332–1339 (2014).
28. Wei, C. Value of combined detection of tumor type M2 pyruvate kinase, tissue polypeptide specific antigen and carcino-embryonic antigen in diagnosis of colorectal cancer. Int J Lab Med35, 2775–2778 (2014).
29. Abdullah, M., Rani, A., Simadibrata, M., Fauzi, A. & Syam, A. The value of fecal tumor M2 pyruvate kinase as a diagnostic tool for colorectal cancer screening. Acta Med Indones44, 94–99 (2012).
30. LI, Y. & WANG, J. Clinical significance of blood and fecal tumor M2-pyruvate kinase expression in patientswith colorectal cancer. J South Med Univ31, 2087–2089 (2011).
31. Haug, U., Hundt, S. & Brenner, H. Sensitivity and specificity of faecal tumour M2 pyruvate kinase for detection of colorectal adenomas in a large screening study. Br. J. Cancer99, 133–135 (2008).
32. Haug, U. et al. Tumour M2-PK as a stool marker for colorectal cancer: Comparative analysis in a large sample of unselected older adults vs colorectal cancer patients. Br. J. Cancer96, 1329–1334 (2007).
33. Koss, K., Maxton, D. & Jankowski, J. A. Z. Faecal dimeric M2 pyruvate kinase in colorectal cancer and polyps correlates with tumour staging and surgical intervention. Color. Dis.10, 244–248 (2008).
34. Zhang, Y., Gu, W., Lin, Z. & Zhiuha, R. Significance of Fecal Tumor M2 Pyruvate Kinase for Detection of Gastrointestinal Cancers. Chin J Gastroenterol12, 465–468 (2007).
35. Shastri, Y. M. et al. Prospective multicenter evaluation of fecal tumor pyruvate kinase type M2 (M2-PK) as a screening biomarker for colorectal ecoplasia. Int. J. Cancer119, 2651–2656 (2006).
36. Tonus, C., Neupert, G. & Sellinger, M. Colorectal cancer screening by non-invasive metabolic biomarker fecal tumor M2-PK. World J. Gastroenterol.12, 7007–7011 (2006).
37. Naumann, M. et al. Faecal pyruvate Kinase type M2 valid screening parameter for colorectal cancer? Preliminary results from a multicenter comparative study. Dtsch Med Wochenschr129, 1806–1807 (2004).
38. Hardt, P. D. et al. Faecal tumour M2 pyruvate kinase: A new, sensitive screening tool for colorectal cancer. Br. J. Cancer91, 980–984 (2004).
39. Khoshbaten, M. et al. Diagnostic value of fecal calprotectin as a screening biomarker for gastrointestinal malignancies. Asian Pacific J. Cancer Prev.15, 1667–1670 (2014).
40. Meucci, G. et al. Diagnostic value of faecal calprotectin in unselected outpatients referred for colonoscopy: A multicenter prospective study. Dig. Liver Dis.42, 191–195 (2010).
41. Damms, A. & Bischoff, S. C. Validation and clinical significance of a new calprotectin rapid test for the diagnosis of gastrointestinal diseases. Int. J. Colorectal Dis.23, 985–992 (2008).
42. Hoff, G. et al. Testing for faecal calprotectin (PhiCal) in the Norwegian Colorectal Cancer Prevention trial on flexible sigmoidoscopy screening: Comparison with an immunochemical test for occult blood (FlexSure OBT). Gut53, 1329–1333 (2004).
43. Carroccio, A. et al. Diagnostic accuracy of fecal calprotectin assay in distinguishing organic causes of chronic diarrhea from irritable bowel syndrome: A prospective study in adults and children. Clin. Chem.49, 861–867 (2003).
44. Costa, F. et al. Role of faecal calprotectin as non-invasive marker of intestinal inflammation. Dig. Liver Dis.35, 642–647 (2003).
45. Summerton, C. B., Longlands, M. G., Wiener, K. & Shreeve, D. R. Faecal calprotectin: A marker of inflammation throughout the intestinal tract. Eur. J. Gastroenterol. Hepatol.14, 841–845 (2002).
46. Tibble, J. A., Sigthorsson, G., Foster, R., Forgacs, I. & Bjarnason, I. Use of surrogate markers of inflammation and Rome criteria to distinguish organic from nonorganic intestinal disease. Gastroenterology123, 450–460 (2002).
47. B. Johne, O. Kronborg, H. I. Tøn, J. A New Fecal Calprotectin Test for Colorectal Neoplasia: Clinical Results and Comparison with Previous Method. Scand. J. Gastroenterol.36, 291–296 (2001).
48. Kristinsson, J. et al. Screening of first degree relatives of patients operated for colorectal cancer: Evaluation of fecal calprotectin vs. Hemoccult II. Digestion64, 104–110 (2001).
49. Tibble, J. et al. Faecal calprotectin and faecal occult blood tests in the diagnosis of colorectal carcinoma and adenoma. Gut49, 402–408 (2001).
50. Tibble, J. et al. A simple method for assessing intestinal inflammation in Crohn’s disease. Gut47, 5006–513 (2000).
51. Røseth, A. G. et al. Faecal calprotectin: A novel test for the diagnosis of colorectal cancer? Scand. J. Gastroenterol.28, 1073–1076 (1993).
52. Turvill, J. et al. Faecal calprotectin in patients with suspected colorectal cancer: A diagnostic accuracy study. Br. J. Gen. Pract.66, e499–e506 (2016).
53. Li, R., Liu, J., Xue, H. & Huang, G. Diagnostic value of fecal tumor M2-pyruvate kinase for CRC screening: A systematic review and meta-analysis. Int. J. Cancer131, 1837–1845 (2012).
54. Tinmouth, J., Lansdorp-Vogelaar, I. & Allison, J. E. Faecal immunochemical tests versus guaiac faecal occult blood tests: What clinicians and colorectal cancer screening programme organisers need to know. Gut64, 1327–1337 (2015).
55. Lee, J. K., Liles, E. G., Bent, S., Levin, T. R. & Corley, D. A. Accuracy of fecal immunochemical tests for colorectal cancer: Systematic review and meta-analysis. Ann. Intern. Med.160, 171–181 (2014).
56. Hirai, H. W. et al. Systematic review with meta-analysis: Faecal occult blood tests show lower colorectal cancer detection rates in the proximal colon in colonoscopy-verified diagnostic studies. Aliment. Pharmacol. Ther.43, 755–764 (2016).
57. Lu, M., Luo, X., Li, N., Chen, H. & Dai, M. Diagnostic accuracy of fecal occult blood tests for detecting proximal versus distal colorectal neoplasia: A systematic review and meta-analysis. Clin. Epidemiol.11, 943–954 (2019).
58. Huang, J. X. et al. Tumor M2-pyruvate kinase in stool as a biomarker for diagnosis of colorectal cancer: A meta-analysis. J. Cancer Res. Ther.10, C225–C228 (2014).
59. Uppara, M. et al. A systematic review and meta-analysis of the diagnostic accuracy of pyruvate kinase M2 isoenzymatic assay in diagnosing colorectal cancer. World J. Surg. Oncol.13, 48 (2015).
60. Haug, U. et al. Tumor M2 pyruvate kinase as a stool marker for colorectal cancer: Stability at room temperature and implications for application in the screening setting. Clin. Chem.52, 782–784 (2006).
61. Ye, X., Huai, J. & Ding, J. Diagnostic accuracy of fecal calprotectin for screening patients with colorectal cancer: A meta-analysis. Turkish J. Gastroenterol.29, 397–405 (2018).